Skip to content
value.today

Immune Design Corp.

🇺🇸 Seattle, Washington, USABiotechnologyFounded 2008

Formerly VACCSYS INC

Total raised
$96 M
3 rounds on record
Latest round
$48 M
Oct 2013
First round on record
Jun 2008
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Immune Design Corp.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2013$48 MNo. 3$10 to $50 million

Immune Design Corp.: Raise no. 3, Oct 2013

Investors in this round

8 investors had bought by the notice of Oct 31, 2013: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Immune Design Corp. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$48 M of $58 M offered; $9 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(c): may be advertised publicly; every buyer must be a verified accredited investor
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Carlos V Paya · Executive Officer, Director
  • James T Rickey · Executive Officer
  • Jan Henrik T ter Meulen · Executive Officer
  • Richard T Kenney · Executive Officer
  • Stephen R Brady · Executive Officer
  • Wayne R Gombotz · Executive Officer
  • Alain V Schreiber · Director
  • Brian V Atwood · Director
  • Bruce V Carter · Director
  • David V Baltimore · Director
  • Ed V Penhoet · Director
  • Peter V Svennilson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Paul Rickey, VP, Finance and Administration. Source: SEC Form D, newest notice filed Oct 31, 2013. Read the notice at the SEC.

equity, optionsSEC
Jul 2010$34 MNo. 2$10 to $50 million

Immune Design Corp.: Raise no. 2, Jul 2010

Investors in this round

6 investors had bought by the notice of Jan 30, 2013: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Immune Design Corp. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$34 M of $34 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Carlos V. Paya · Executive Officer, Director
  • David Paul Parker · Executive Officer
  • James Paul Rickey · Executive Officer
  • Wayne Paul Gombotz · Executive Officer
  • Alain V. Schreiber · Director
  • Brian V. Atwood · Director
  • Bruce LA Carter · Director
  • David V. Baltimore · Director
  • Edward V. Penhoet · Director
  • Roger V. Perlmutter · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by J. Paul Rickey, VP, Finance/Admin.. Source: SEC Form D and 3 amendments, newest notice filed Jan 30, 2013. Read the notice at the SEC.

equitySEC
Jun 2008$14 MNo. 1$10 to $50 million

Immune Design Corp.: Raise no. 1, Jun 2008

Investors in this round

4 investors had bought by the notice of Jul 8, 2009: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Immune Design Corp. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$14 M of $18 M offered; $4 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Steven Reed · Executive Officer, Director
  • Brian Atwood · Director
  • David Baltimore · Director
  • Ed Penhoet · Director
  • Richard Klausner · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Proceeds will be used for working capital.”

Signed by Steven G. Reed, President. Source: SEC Form D, newest notice filed Jul 8, 2009. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Immune Design Corp. chose not to state its revenue in its newest notice of a funding round (Oct 2013).

    SEC Form D · Oct 2013

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Oct 2013

That is all the official record says: Immune Design Corp. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

8 named in official filings. Open an investor to see everything it has backed.

Investors in Immune Design Corp.
InvestorKindAmountRoundRoleSource
Alta Partners Management VIII, LLCFund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Alta Partners VIII, L.P.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Column Group GP, LPFund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Column Group L.P.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
ProQuest Associates IV LLCOthernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
ProQuest Investments IV, L.P.Fund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Versant Side Fund III, L.P.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Versant Venture Capital III, L.P.Venture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 8 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Immune Design Corp.
NameRoleNamed in
Carlos V PayaExecutive officerOct 2013
James T RickeyExecutive officerOct 2013
Jan Henrik T ter MeulenExecutive officerOct 2013
Richard T KenneyExecutive officerOct 2013
Stephen R BradyExecutive officerOct 2013
Wayne R GombotzExecutive officerOct 2013
Carlos V. PayaExecutive officerJan 2013
David Paul ParkerExecutive officerJan 2013
James Paul RickeyExecutive officerJan 2013
Wayne Paul GombotzExecutive officerJan 2013
Steve ReedExecutive officerOct 2011
Bruce CarterExecutive officerAug 2010
Sammy FarahExecutive officerAug 2010
Thomas DubenskyExecutive officerAug 2010
Steven ReedExecutive officerJul 2009
Alain V SchreiberDirectorOct 2013
Brian V AtwoodDirectorOct 2013
Bruce V CarterDirectorOct 2013
Carlos V PayaDirectorOct 2013
David V BaltimoreDirectorOct 2013
Ed V PenhoetDirectorOct 2013
Peter V SvennilsonDirectorOct 2013
Alain V. SchreiberDirectorJan 2013
Brian V. AtwoodDirectorJan 2013
Bruce LA CarterDirectorJan 2013
Carlos V. PayaDirectorJan 2013
David V. BaltimoreDirectorJan 2013
Edward V. PenhoetDirectorJan 2013
Roger V. PerlmutterDirectorJan 2013
Alain SchreiberDirectorOct 2011
Brian AtwoodDirectorOct 2011
Bruce CarterDirectorOct 2011
David BaltimoreDirectorOct 2011
Edward PenhoetDirectorOct 2011
Richard KlausnerDirectorOct 2011
Steve ReedDirectorOct 2011
Ed PenhoetDirectorJul 2009
Steven ReedDirectorJul 2009